ASCO: Elinzanetant Cuts Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
By Elana Gotkine HealthDay Reporter
TUESDAY, June 3, 2025 -- For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive breast cancer, elinzanetant, a neurokinin-targeted therapy, reduces the frequency of vasomotor symptoms, according to a study published online June 2 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.
Fatima Cardoso, M.D., from the Champalimaud Foundation in Lisbon, Portugal, and colleagues performed a phase 3 trial involving women aged 18 to 70 years with moderate-to-severe vasomotor symptoms associated with endocrine therapy for HR-positive breast cancer or its prevention. Women were randomly assigned to receive once-daily elinzanetant at a dose of 120 mg for 52 weeks or once-daily placebo for 12 weeks followed by once-daily elinzanetant at a dose of 120 mg for 40 weeks (316 and 158 patients, respectively). Only one of the patients was taking endocrine therapy for breast cancer prevention.
The researchers found that the mean change from baseline in the mean daily frequency of moderate-to-severe vasomotor symptoms at week 4 was −6.5 and −3.0 episodes for those receiving elinzanetant and placebo, respectively (least-squares mean difference, −3.5 episodes). The mean change was −7.8 and −4.2 episodes among those receiving elinzanetant and placebo, respectively, at week 12 (least-squares mean difference, −3.4 episodes). Overall, 69.8 and 62.0 percent of those receiving elinzanetant and placebo, respectively, reported at least one adverse event during weeks 1 through 12; serious adverse events occurred in 2.5 and 0.6 percent, respectively.
"In a finding consistent with the results of previous trials involving postmenopausal women, treatment with elinzanetant resulted in significant decreases in the frequency of vasomotor symptoms and in sleep disturbances and improvements in health-related quality of life among women with moderate-to-severe vasomotor symptoms taking endocrine therapy for breast cancer," the authors write.
Several authors disclosed ties to Bayer, which is developing elinzanetant and funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Rate of Sexual Dysfunction Similar in Middle-Aged, Older Women
MONDAY, Aug. 18, 2025 -- Older women experience female sexual dysfunction (FSD) at similar rates as midlife women but report less sexual distress, according to a study published...
Increasing Sit-to-Stand Transitions Lowers BP in Postmenopausal Women
FRIDAY, Aug. 8, 2025 -- Changing sedentary behaviors is feasible for postmenopausal women with overweight and obesity, and increasing sit-to-stand transitions (STSTs) is...
Stopping Menopausal Hormone Therapy May Temporarily Increase Fracture Risk
WEDNESDAY, July 30, 2025 -- Stopping menopausal hormone therapy initially leads to several years of elevated fracture risk; however, this risk then decreases, first becoming...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.